Fedratinib for the treatment of myelofibrosis: a critical appraisal of clinical trial and "real-world" data

Adrian Duek ¹, Ilona Leviatan ², Osnat Jarchowsky Dolberg ^2,3

⁰Hematology Unit, University Hospital Samson Assuta, Ashdod, Israel.

Blood Cancer Journal +

|

January 14, 2025

View abstract on PubMed

Summary

Fedratinib shows efficacy in myelofibrosis (MF), but real-world responses are less robust than in clinical trials. Timely recognition of treatment failure is key for effective MF management.

Area Of Science

Hematology
Oncology
Pharmacology

Background

Fedratinib is a JAK2 inhibitor approved for intermediate-2 or high-risk myelofibrosis (MF).
It offers an alternative to ruxolitinib, particularly for patients with thrombocytopenia.
Clinical trial data show significant spleen and symptom improvements with fedratinib.

Purpose Of The Study

To compare fedratinib's efficacy in clinical trials versus real-world practice for myelofibrosis.
To investigate factors influencing fedratinib's effectiveness in routine clinical settings.
To emphasize the importance of defining treatment failure for optimal MF therapy sequencing.

Main Methods

Analysis of randomized clinical trial data for fedratinib efficacy.
Review of recently published real-world data on fedratinib use in MF.
Comparison of spleen volume reduction and symptom score improvements between trial and real-world settings.

Main Results

Clinical trials demonstrated ~30-45% spleen volume reduction and 35-40% symptom improvement with fedratinib.
Real-world data indicate lower response rates, with spleen responses in 13-68% and variable symptom improvement.
Discrepancies may stem from inconsistent definitions of ruxolitinib failure impacting fedratinib initiation timing.

Conclusions

Fedratinib's real-world effectiveness in myelofibrosis may be less pronounced than observed in clinical trials.
A standardized definition of ruxolitinib failure is crucial for optimizing fedratinib's role as a second-line therapy.
Timely transition to effective treatments, like fedratinib, hinges on accurately identifying treatment failure in myelofibrosis management.